Press Room

2008 Press Releases

TSX:V - IXS
NASD OTC:BB: IXSBF

June 12, 2008

InNexus Biotechnology Announces Expansion of Patent Protection of DXL™ Technology -- Company Receives Allowance of Patent Claims from both US and European Patent Offices --

BRITISH COLUMBIA, Canada - 12 June 2008 - InNexus Biotechnology Inc. (OTCBB: IXSBF)(TSX VENTURE: IXS), (http://www.ixsbio.com), a drug development company commercializing the next generation of monoclonal antibodies based on its technology, Dynamic Cross Linking (DXL™), announced today that it has received notices of allowance on several of its patent applications both in the United States Patent & Trademark Office (USPTO) and in the European Patent Office (EPO) covering its DXL™ technology. The patents following issuance will be titled "THERAPEUTIC APPLICATIONS OF NONCOVALENT DIMERIZING ANTIBODIES" in the U.S. and "METHOD OF AFFINITY CROSS-LINKING BIOLOGICALLY ACTIVE, IMMUNOGENIC PEPTIDES TO ANTIBODIES" in Europe, and relate to the Company’s ability to develop and manufacture DXL™ antibodies. The new patents name InNexus scientists as inventors and are solely owned by InNexus.

"This significantly expands the intellectual property protection of our exclusive DXL™ technology and continues to demonstrate both its potential as a novel and versatile therapeutic drug development system. Obtaining broad patent protection of technology is not only essential to the success of a biotech company, it’s the currency of our business”, said Jeff Morhet, Chairman and CEO of InNexus. “We are very pleased that we will be expanding our DXL™ patent portfolio both here in the U.S. and abroad and we will continue to aggressively pursue broad protection of the various aspects of DXL™ technology. A solid patent portfolio will allow us to drive value into the company with the potential for future licensing deals or outright sales of our maturing pre-clinical candidates.”

Dynamic Cross Linking (DXL™) technology seeks to improve upon the therapeutic potency of monoclonal antibody products by increasing target antigen binding, enhancing antibody effector functions, and installing new properties into antibodies such as the ability to trigger apoptosis, or "cell suicide". Put simply, DXL™ allows antibodies to achieve a higher level of therapeutic usefulness.

About InNexus

InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its DXL™ technology, which improves the potency of existing antibody products while opening new markets and disease applications. DXL™ antibodies utilize unique, novel and patented methods and technologies of InNexus.

InNexus is headquartered in British Columbia with principal management based in Scottsdale, Arizona on the campus of Mayo Clinic and has its own in-house developmental facilities. These development resources provide validation of protein and peptide discoveries, enabling InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics. To learn more about InNexus, please visit www.ixsbio.com.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. This news release may contain assumptions, estimates, and other forward-looking statements that involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control, that may cause actual results or performance to differ materially from those currently anticipated in such statements.

Contact: Jeff Morhet
Chairman & Chief Executive Officer
InNexus Biotechnology Inc.
480-862-7500